TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - MODERNA | Market Closed - Boerse Frankfurt Warrants 03:48:22 2024-07-11 pm EDT | ||
| 4.38 EUR | -10.79% |
|
| Current month | -9.32% | ||
| 1 month | +104.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 4.38 | -10.79% |
| 24-07-10 | 4.91 | -2.39% |
| 24-07-09 | 5.03 | +0.20% |
| 24-07-08 | 5.02 | +4.15% |
| 24-07-05 | 4.82 | +0.84% |
Real-time Boerse Frankfurt Warrants
Last update July 11, 2024 at 03:48 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SW6WZJ |
| ISIN | DE000SW6WZJ0 |
| Date issued | 2024-05-24 |
| Strike | 169.6 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.35 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.22 € |
|---|---|
| Lowest since issue | 0.35 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
122.8
USD
Average target price
145.9
USD
Spread / Average Target
+18.79%
- Stock Market
- Certificates
- Certificat
